In July, an Indivior subsidiary pleaded guilty to a felony for false declarations connected to health care matters, and together with Indivior, consented to pay an extra $600 million to fix liability to the United States related to the marketing of Suboxone.
Shaun Thaxter, the previous CEO of Indivior, was sentenced Oct. 22 to six months in federal jail for his role in a plan to mislead payers, physicians and patients about the security of its opioid dependency treatment drug, Suboxone..
Suboxone is designed to treat opioid dependency by minimizing withdrawal symptoms, but it consists of buprenorphine, a powerful and addictive opioid. Mr. Thaxter and others at Indivior mislead payers, doctors and clients about the safety of the drug, the U.S. Justice Department charged..
Suboxone generated nearly all of Indiviors profits, according to the Justice Department..
” Misrepresentations made about the drug, while Thaxter ran the company, misguided MassHealth about the potential threat of accidental opioid exposure. It is untenable to willfully neglect requirements that treatment medications be recommended carefully in order to protect patient health and wellness,” said Elton Malone, assistant inspector general for examinations with HHS.
Check Out the Justice Departments complete news release here.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.
More posts on pharmacy: Remdesivir becomes very first FDA-approved COVID-19 treatmentConvalescent plasma reveals no benefit for COVID-19 clients in medical trialA breakdown of the 4 COVID-19 vaccine trials in late-stage testing.
Mr. Thaxter also was ordered to pay a fine of $100,000 and surrender $500,000. He pleaded guilty to a one-count misdemeanor on June 30 for his role in the scheme. He served as CEO of Indivior from 2009 to quickly prior to his guilty plea..
Mr. Thaxter also was purchased to pay a fine of $100,000 and surrender $500,000. He pleaded guilty to a one-count misdemeanor on June 30 for his function in the scheme. Prosecutors stated Mr. Thaxter asked his staff members to develop a strategy to win favored status for Suboxone in Massachusetts Medicaid program, MassHealth. To do so, Indivior workers shared false and misleading safety information to MassHealth officials about Suboxones dangers for unexpected pediatric exposure, district attorneys stated.
Maia Anderson –
Friday, October 23rd, 2020
In August, Indiviors former medical director, Timothy Baxter, also pleaded guilty to a misdemeanor for an infraction of the federal Food, Drug, and Cosmetic Act related to the marketing of Suboxone.
District attorneys said Mr. Thaxter asked his employees to design a method to win preferred status for Suboxone in Massachusetts Medicaid program, MassHealth. To do so, Indivior workers shared deceptive and false safety information to MassHealth officials about Suboxones risks for unintentional pediatric direct exposure, district attorneys stated. Two months after receiving the false information, MassHealth stated it would offer access to Suboxone for Medicaid patients with kids under age 6, according to the Justice Department..
” While Thaxter served for several years as Indiviors president, he remained in a position to make sure that insurers, doctors and clients were handled truthfully. Instead, Thaxter failed to prevent efforts to build revenues through misleading safety claims, which caused millions of dollars in ill-gotten gains for Indivior,” stated acting U.S. Attorney Daniel Bubar.